Gufic Biosciences shareholders approved all five ordinary and special resolutions at its 42nd Annual General Meeting held on September 4, 2026. The company declared a 10% final dividend, amounting to ₹0.10 per equity share of face value ₹1 each, for the financial year ended March 31, 2026.

The meeting was conducted via video conferencing from Mumbai. Mr. Jayesh P. Choksi, Chairman & Managing Director, chaired the session. All directors and committee chairpersons were present. Statutory auditors, secretarial auditors, and the scrutinizer also attended.

Voting Participation and Results

A total of 43 shareholders participated in the meeting, comprising 5 from the promoter group and 38 from the public category. Corporate shareholders holding 3,13,60,802 equity shares (representing 31.27% of paid-up capital) submitted authorized representations.

The consolidated scrutinizer report, issued by CS Sandhya R. Malhotra of M/s. Manish Ghia & Associates on September 7, 2026, confirmed that all resolutions were passed with requisite majorities. The record date for voting was August 28, 2026, with a total of 30,441 shareholders on record.

Resolution-wise Voting Breakdown

The promoter group voted in favor of 100% of their holdings across all resolutions. Public institutional investors also voted unanimously in favor. Minor dissent was observed only among non-institutional public shareholders, particularly regarding the special resolution for Mr. Pankaj J. Gandhi’s re-appointment.

Key Resolutions Approved

Shareholders approved several key items during the proceedings:

• Adoption of the audited standalone and consolidated financial statements for FY26.
• Re-appointment of Mr. Pranav J. Choksi as a director upon retirement by rotation.
• Ratification of remuneration for cost auditors M/s. Poddar & Co. for FY27.
• Re-appointment of Mr. Pankaj J. Gandhi as Whole Time Director and continuation of his directorship beyond age 70.

Ms. Ami Shah, Company Secretary & Compliance Officer, confirmed that remote e-voting was facilitated through NSDL. The audit reports for FY25-26 contained no qualifications or adverse remarks.

Gufic Biosciences promoted two senior executives to key leadership positions effective September 2, 2026. The board approved the changes following a recommendation from the Nomination & Remuneration Committee.

Ms. Ami Shah was promoted to Head-Legal while retaining her role as Company Secretary & Compliance Officer. Mr. Pinak Padhya was elevated from Vice President to President – Sales & Marketing.

Regulatory Disclosure

The company issued an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure complies with Part A of Schedule III of the Listing Regulations.

Executive Profiles

Ms. Shah holds a law degree (LL.B.) and is a qualified Company Secretary. She has served Gufic Biosciences for over 10 years. Her responsibilities include corporate governance, statutory compliance, and managing intellectual property matters.

Mr. Padhya brings over 28 years of experience in the pharmaceutical industry. He holds an MBA in Marketing and a Pharmacy Graduate degree. His previous roles include positions at Sun Pharma, Ranbaxy, Glenmark, Elder, Medley, and Cadila Pharma.

Key Responsibilities

Ms. Shah continues to serve as a Key Managerial Personnel. Her background includes drafting commercial agreements and handling litigation. She previously worked with the JM Baxi Group as Senior Executive – Secretarial Team.

Mr. Padhya’s expertise covers multiple therapeutic areas including Orthopaedics, Gastrointestinal, Gynaecology, Herbal, Dermatology, Pediatrics, and General Practice. He focuses on strategic brand building and cluster growth.